ketamine
Evaluating oral ketamine's adverse side effects in chronic pain patients (Hom, et al, 2025)
Evaluating oral ketamine’s adverse side effects in chronic pain patients - PubMedOur results suggest that at daily doses above
ketamine
Spotlight: Comparative Effects of Repeated Ketamine Infusion Versus Intranasal Esketamine in Patients With Treatment-Resistant Depression: A Retrospective Chart Review (Meisner, et al, 2025)
"In this naturalistic sample of patients with similarly severe TRD treated in a ketamine subspecialty service over a 4–5-week induction period, treatment with IV racemic ketamine was associated with a more rapid response and greater overall efficacy than treatment with IN esketamine."
lsd
Spotlight: Chris Bache: LSD and the Mind of the Universe
"experiences and insights from 73 high-dose LSD sessions conducted between 1979 and 1999"
psychedelic experience
Religious Scholar studies LSD experience and decides "You Can Have Too Much Transcendence" (2023)
"I had to sit still on my cushion, in my life, and let those memories and the energies that I accessed, in those hours, soak into my physical being."
consciousness
What if the molecular machines that read and write your DNA are quantum? (Goel, Busstra, 2025)
"Busstra, Goel talk about experiment and explore the new theoretical framework it could lead to: a new physics to understand life, living systems and consciousness."
ketamine
Spotlight: Ketamine's Therapeutic Role in Substance Use Disorders: A Narrative Review (Thomas, et al, 2025)
"...ketamine has been tested in nine RBCTs targeting cocaine, alcohol, opioid use disorder, and nicotine, suggesting efficacy for addiction in combination with psychotherapies, and often when doses produce subjectively reported mystical or psychedelic experiences."
ketamine
Ketamine/esketamine in the treatment of depression with comorbid borderline personality disorder or traits: A systematic review of effectiveness (Scott, et al, 2025)
"patients with depression and comorbid borderline personality disorder/traits were equally likely to respond to ketamine/esketamine as those with depression but without borderline personality disorder/traits."
ketamine
Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population (Hughes, et al, 2025)
"Ketamine's use for pediatric TRD demonstrated rapid-onset relief for signs and symptoms of depression in children and adolescents, and psilocybin also decreased symptoms in patients with longstanding or refractory depression. Ketamine has been well tolerated and exhibited symptom improvements"
ketamine
Psychedelics and mental health: reimagining care through science, insight, and compassion (Mikellides, et al, 2025)
"These substances are not stand-alone medications; rather, they function as adjuncts to intensive psychotherapeutic processes. Training therapists and establishing ethical, evidence-based protocols is essential."
ketamine
Mindfulness, music, visual occlusion in ketamine therapy for depression: do they change outcomes? A qualitative and quantitative analysis of a randomized controlled trial (Kheirkhah, et al, 2025)
"...participants in the combined sensory intervention group reported deeper engagement, a stronger sense of connection to reality, increased focus on the experience..., moments of relief from sadness, and feelings of awe and spiritual insight compared to the control group. "
ketamine
Ketamine Reduces Suicidality-Associated Emergency Department Utilization in Patients With Treatment-Resistant Depression: A 6-Month Mirror-Image Study (Patarroyo-Rodriguez, et al, 2025)
La ketamina reduce la utilización del departamento de emergencias asociada a la suicidabilidad en pacientes con depresión resistente al tratamiento: un estudio de imagen especular de 6 meses
ketamine
Vascular endothelial growth factor: a key factor in the onset and treatment of depression (Wang, et al, 2025)
Factor de crecimiento endotelial vascular: un factor clave en la aparición y tratamiento de la depresión
antidepressants
Spotlight: Large responses to antidepressants or methodological artifacts? A secondary analysis of STAR∗D, a single-arm, open-label, nonindustry antidepressant trial (Xu, et al, 2025)
"...our results do not support the notion that a subgroup of patients with a large response exists. Instead, these findings support the assumption that the putative subgroups from industry randomized controlled trials may be artifacts caused by methodological biases."
psilocybin
Spotlight: Depression remission endures 5 years after psilocybin trial consisting of psilocybin with psychotherapy (2025)
"when it comes to reducing depression with psychedelic-assisted therapy, what matters even more than the drug is a strong relationship between the therapist and study participant."
Reducción de Daños Psicodélicos
La Reducción de Daños Psicodélicos
La Reducción de Daños Psicodélicos comienza con la educación
dmt
Spotlight: N,N-dimethyltryptamine effects on connectome harmonics, subjective experience and comparative psychedelic experiences (Vohryzek, et al, 2025)
"the connectome harmonic repertoire under N,N-dimethyltryptamine (DMT) is reshaped in line with other reported psychedelic compounds - psilocybin, lysergic acid diethylamide (LSD) and ketamine... the repertoire entropy of connectome harmonics increases under DMT, as with those other psychedelics."
ketamine
Spotlight: "Ketamine States: A Journey Through the Mind" (Wolfson, et al, 2025)
Estados de la ketamina: Un viaje a través de la mente
ketamine
Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective—a new and evolving approach (Wolfson & Vaid, 2024)
"in a conducive set and settings, these experiences have been demonstrated to be of positive use in psychiatry and psychotherapy, providing a time-out from usual states of mind to facilitate a reshaping of self-experience along with symptomatic relief."
